title: [Fungal (Candida) infections in the immunocompromised pediatric patient].
abstract: Today, mycotic infections in immunocompromised patients are mainly caused by Candida spp. and Aspergillus spp. The patients most sensitive to these infections are those with some kind of cell-mediated immunity quantitative or qualitative alteration (i.e., blood-related cancer, primary or secondary neutropenia, immunosuppressive disease or therapy, etc.). Candida infection in the immunosupressed patient comprises a wide range of serious diseases such as candidemia, chronic disseminated candididasis, endocarditis, meningitis and endophthalmitis. Therefore, infection by Candida spp. is considered secondary to the technological and medical advances which extend the life of patients with chronic diseases.
authors.affiliation: Hospital Infantil de Mexico Federico Gomez, SSA, Mexico, DF.
authors.forename: J
authors.initials: J
authors.lastname: Bruce Diemond
authors.forename: C
authors.initials: C
authors.lastname: Lopez
authors.forename: F
authors.initials: F
authors.lastname: Huerta Romano
authors.forename: C
authors.initials: C
authors.lastname: Montiel Castillo
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000276:immunology / Q000382:microbiology; D002177:Candidiasis / Q000453:epidemiology / Q000276:immunology* / Q000382:microbiology* / Q000628:therapy; D002648:Child; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects
chemical_list: D000935:Antifungal Agents; D007166:Immunosuppressive Agents